KRAS and lung carcinoma: ZNF304 is not highly expressed in lung tumors and its expression is significantly anti-correlated with UHRF1 expression in lung adenocarcinoma patients carrying a KRAS mutation (Supplementary Fig. 7c), suggesting that UHRF1 may instead mediate this phenotype in KRAS-driven lung cancer.